journal article·2022-05-25Open access

Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids

Peiru Chen, Dali Wang, Yuyan Wang, Lei Zhang, Qiwei Wang, Lanxia Liu, Jiahe Li, Xin Sun, Mengqi Ren, Ruoxuan Wang, Yang Fang, Jean J. Zhao, Ke Zhang

Nano Letters· Volume 22· Issue 10

Abstract

Nucleic-acid-based immune adjuvants have been extensively investigated for the design of cancer vaccines. However, nucleic acids often require the assistance of a carrier system to improve cellular uptake. Yet, such systems are prone to carrier-associated adaptive immunity, leading to difficulties in a multidose treatment regimen. Here, we demonstrate that a spherical nucleic acid (SNA)-based self-adjuvanting system consisting of phosphodiester oligonucleotides and vitamin E can function as a potent anticancer vaccine without a carrier. The two functional modules work synergistically, serving as each other’s delivery vector to enhance toll-like receptor 9 activation. The vaccine rapidly enters cells carrying OVA model antigens, which enables efficient activation of adaptive immunity in vitro and in vivo. In OVA-expressing tumor allograft models, both prophylactic and therapeutic vaccinations significantly retard tumor growth and prolong animal survival. Furthermore, the vaccinations were also able to reduce lung metastasis in a B16F10-OVA model.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departments of Chemistry and Chemical Biology, Chemical Engineering, and Bioengineering, Northeastern University, Boston, Massachusetts 02115, United States

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Department of Bioengineering, Northeastern University, Boston, Massachusetts 02115, United States

Funding

National Cancer Institute · National Institute of General Medical Sciences · Division of Materials Research

References (36)

Show source-provided references
1. 10.1038/nri.2016.7810.1038/nri.2016.78 ↗
2. 10.1146/annurev-immunol-031210-10134010.1146/annurev-immunol-031210-101340 ↗
3. 10.1038/s41577-020-0288-310.1038/s41577-020-0288-3 ↗
4. 10.3389/fchem.2020.0060110.3389/fchem.2020.00601 ↗
5. Shukla N. M. · 201810.1021/acsmedchemlett.8b00566 ↗
6. 10.1002/med.2164910.1002/med.21649 ↗
7. 10.1126/scitranslmed.aaz660610.1126/scitranslmed.aaz6606 ↗
8. 10.1016/j.apsb.2021.12.0210.1016/j.apsb.2021.12.02 ↗
9. 10.1016/j.matt.2020.08.02710.1016/j.matt.2020.08.027 ↗
10. 10.1080/2162402X.2020.177762510.1080/2162402X.2020.1777625 ↗
11. 10.4161/onci.2093110.4161/onci.20931 ↗
12. 10.1073/pnas.190280511610.1073/pnas.1902805116 ↗
13. 10.1021/acsnano.7b0097810.1021/acsnano.7b00978 ↗
14. 10.1038/s41551-019-0351-110.1038/s41551-019-0351-1 ↗
15. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
16. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
17. 10.1021/acsami.9b2107510.1021/acsami.9b21075 ↗
18. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
19. 10.1016/j.jconrel.2020.03.04010.1016/j.jconrel.2020.03.040 ↗
20. 10.1016/j.nano.2013.02.00610.1016/j.nano.2013.02.006 ↗
21. 10.1016/j.vaccine.2010.02.10310.1016/j.vaccine.2010.02.103 ↗
22. 10.1021/jacs.5b0079510.1021/jacs.5b00795 ↗
23. 10.1158/0008-5472.CAN-12-025710.1158/0008-5472.CAN-12-0257 ↗
24. 10.1016/S0264-410X(98)00151-010.1016/S0264-410X(98)00151-0 ↗
25. 10.1021/jacs.6b0755410.1021/jacs.6b07554 ↗
26. 10.3382/ps.074066610.3382/ps.0740666 ↗
27. 10.1586/erv.10.17410.1586/erv.10.174 ↗
28. 10.1038/sj.onc.121091110.1038/sj.onc.1210911 ↗
29. 10.1016/B978-0-12-804019-5.00009-810.1016/B978-0-12-804019-5.00009-8 ↗
30. 10.1002/adma.20160603610.1002/adma.201606036 ↗
31. 10.1002/eji.183021113610.1002/eji.1830211136 ↗
32. 10.1021/bi991393l10.1021/bi991393l ↗
33. 10.1016/j.celrep.2015.04.00910.1016/j.celrep.2015.04.009 ↗
34. 10.1038/nrc.2015.310.1038/nrc.2015.3 ↗
35. 10.1073/pnas.130580411010.1073/pnas.1305804110 ↗
36. 10.3382/ps.070170910.3382/ps.0701709 ↗